Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Rad51 on Survival of A549 Cells

  • Yu, Sha-Sha (Department of Pathology, The First Affiliated Hospital of Nanchang University) ;
  • Tu, Yi (Department of Pathology, The First Affiliated Hospital of Nanchang University) ;
  • Xu, Lin-Lin (Department of Scientific Research Center, The First Affiliated Hospital of Nanchang University) ;
  • Tao, Xue-Qin (Department of Pathology, The First Affiliated Hospital of Nanchang University) ;
  • Xu, Shan (Department of Pathology, The First Affiliated Hospital of Nanchang University) ;
  • Wang, Shan-Shan (Department of Pathology, The First Affiliated Hospital of Nanchang University) ;
  • Xiong, Yi-Feng (Department of Pathology, The First Affiliated Hospital of Nanchang University) ;
  • Mei, Jin-Hong (Department of Pathology, The First Affiliated Hospital of Nanchang University)
  • Published : 2015.02.04
Download PDF
⟨ Previous Next ⟩

Abstract

Rad51, a key factor in the homologous recombination pathway for the DNA double-strand break repair, plays a vital role in genesis of non-small-cell lung cancer (NSCLC). In recent years, more and more studies indicate that high expression of Rad51 is of great relevance to resistance of NSCLC to chemotherapeutic agents and ionizing radiation. However, the underlying molecular mechanisms are poorly understood. In this study, we investigated the role of single Rad51 on cell viability in vitro. Our results show that depletion of endogenous Rad51 is sufficient to inhibit the growth of the A549 lung cancer cell line, by accumulating cells in G1 phase and inducing cell death. We conclude that independent Rad51 expression is critical to the survival of A549 cells and can be an independent prognostic factor in NSCLC patients.

Keywords

References

  1. Allera-Moreau C, Rouquette I, Lepage B, et al (2012). DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients. Oncogenesis, 1, 30. https://doi.org/10.1038/oncsis.2012.29
  2. Bindra RS, Schaffer PJ, Meng A, et al (2004). Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol, 24, 8504-18. https://doi.org/10.1128/MCB.24.19.8504-8518.2004
  3. Clemenson C, Marsolier-Kergoat M-C (2009). DNA damage checkpoint inactivation: adaptation and recovery. DNA Repair, 8, 1101-9. https://doi.org/10.1016/j.dnarep.2009.04.008
  4. Collis S, Tighe A, Scott S, et al (2001). Ribozyme minigenemediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res, 29, 1534-8. https://doi.org/10.1093/nar/29.7.1534
  5. Farmer H, McCabe N, Lord CJ, et al (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-21. https://doi.org/10.1038/nature03445
  6. Fayaz S, Karimmirza M, Tanhaei S, et al (2013). Increased risk of differentiated thyroid carcinoma with combined effects of homologous recombination repair gene polymorphisms in an Iranian population. Asian Pac J Cancer Prev, 14, 6727-31 https://doi.org/10.7314/APJCP.2013.14.11.6727
  7. Feng Z, Scott SP, Bussen W, et al (2011). Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci, 108, 686-91. https://doi.org/10.1073/pnas.1010959107
  8. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  9. Franchitto A, Pichierri P, Piergentili R, et al (2003). The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene, 22, 2110-20. https://doi.org/10.1038/sj.onc.1206254
  10. Gajra A, Newman N, Gamble GP, et al (2003). Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer, 42, 51-7. https://doi.org/10.1016/S0169-5002(03)00285-X
  11. Hine CM, Li H, Xie L, et al (2014). Regulation of Rad51 promoter. Cell Cycle, 13, 0-1.
  12. Hine CM, Seluanov A, Gorbunova V (2008). Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA, 105, 20810-5. https://doi.org/10.1073/pnas.0807990106
  13. Kauffmann A, Rosselli F, Lazar V, et al (2007). High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene, 27, 565-73.
  14. Ko J-C, Hong J-H, Wang L-H, et al (2008). Role of repair protein Rad51 in regulating the response to gefitinib in human nonsmall cell lung cancer cells. Mol Cancer Ther, 7, 3632-41. https://doi.org/10.1158/1535-7163.MCT-08-0578
  15. Lee PS, Fang J, Jessop L, et al (2014). RAD51B activity and cell cycle regulation in response to DNA damage in breast cancer cell lines. Breast Cancer, 8, 135.
  16. Liu Y, Maizels N (2000). Coordinated response of mammalian Rad51 and Rad52 to DNA damage. EMBO Rep, 1, 85-90. https://doi.org/10.1093/embo-reports/kvd002
  17. Maacke H, Jost K, Opitz S, et al (2000). DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene, 19, 2791-5. https://doi.org/10.1038/sj.onc.1203578
  18. Maher P, Dargusch R, Ehren JL, et al (2011). Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PLoS One, 6, 21226. https://doi.org/10.1371/journal.pone.0021226
  19. Mukherjee A, Karmakar P (2013). Attenuation of PTEN perturbs genomic stability via activation of Akt and down regulation of Rad51 in human embryonic kidney cells. Mol Carcinog, 52, 611-8. https://doi.org/10.1002/mc.21903
  20. Nogueira A, Assis J, Catarino R, et al (2013). DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. Pharmacogenomics, 14, 689-700. https://doi.org/10.2217/pgs.13.48
  21. Petermann E, Orta ML, Issaeva N, et al (2010). Hydroxyureastalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell, 37, 492-502. https://doi.org/10.1016/j.molcel.2010.01.021
  22. Putnam CD, Jaehnig EJ, Kolodner RD (2009). Perspectives on the DNA damage and replication checkpoint responses in Saccharomyces cerevisiae. DNA Repair, 8, 974-82. https://doi.org/10.1016/j.dnarep.2009.04.021
  23. Qiao G, Wu Y, Yang X, et al (2005). High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer, 93, 137-43. https://doi.org/10.1038/sj.bjc.6602665
  24. Raderschall E, Stout K, Freier S, et al (2002). Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res, 62, 219-25.
  25. Richardson C, Stark JM, Ommundsen M, et al (2004). Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene, 23, 546-53. https://doi.org/10.1038/sj.onc.1207098
  26. Segura MM, Mangion M, Gaillet B, et al (2013). New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther, 13, 987-1011. https://doi.org/10.1517/14712598.2013.779249
  27. Tennstedt P, Fresow R, Simon R, et al (2013). RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer, 132, 2118-26. https://doi.org/10.1002/ijc.27907
  28. Thompson LH, Schild D (2002). Recombinational DNA repair and human disease. Mutat Res Fundam Mol Mech Mutagen, 509, 49-78. https://doi.org/10.1016/S0027-5107(02)00224-5
  29. Yamamori T, Meike S, Nagane M, et al (2013). ER stress suppresses DNA double-strand break repair and sensitizes tumor cells to ionizing radiation by stimulating proteasomal degradation of Rad51. FEBS Lett, 20, 3348-53.

Cited by

  1. RAD51 regulates CHK1 stability via autophagy to promote cell growth in esophageal squamous carcinoma cells vol.37, pp.12, 2016, https://doi.org/10.1007/s13277-016-5455-6